Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.
复制标题
伊马替尼治疗期间慢性粒细胞白血病动态的异质性：免疫反应的作用。
DOI：
10.1098/rspb.2009.2179
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Wodarz,Dominik
中科院分区：
文献类型：
--
作者：
Wodarz,Dominik
先前的研究表明，在伊马替尼治疗期间，慢性粒细胞白血病 BCR-ABL 转录本数量的下降在平均数据集中经历了快速阶段和缓慢阶段。耐药性导致再生。在本文中，研究了患者之间治疗反应的差异。快速下降阶段和慢速下降阶段的斜率之间存在显着的正相关性。缓慢下降阶段和再生阶段的斜率之间存在显着的负相关。快速下降阶段和再生阶段的斜率之间没有发现相关性。成功适应不同临床特征的数学模型通过调用免疫反应作为治疗期间肿瘤衰退的关键决定因素来解释这些相关性。在药物治疗期间增强免疫力可以增强患者对治疗的反应。
Previous studies have shown that during imatinib therapy, the decline of chronic myeloid leukaemia BCR-ABL transcript numbers involves a fast phase followed by a slow phase in averaged datasets. Drug resistance leads to regrowth. In this paper, variation of treatment responses between patients is examined. A significant positive correlation is found between slopes of the fast and the slow phase of decline. A significant negative correlation is found between slopes of the slow phase of decline and the regrowth phase. No correlation is found between slopes of the fast phase of decline and the regrowth phase. A mathematical model that is successfully fitted to diverse clinical profiles explains these correlations by invoking the immune response as a key determinant of tumour decline during treatment. Boosting immunity during drug therapy could enhance the response to treatment in patients.